November 30, 2025Discover OncologyOpen Access

Prognostic and therapeutic response prediction in glioblastoma multiforme using a lactylation-associated gene signature

View Full Paper

Ask AI

Bookmark

Predictive efficacy shows robust outcomes in glioblastoma treatment strategies, indicating potential clinical applications.
Key evidence highlights the gene signature's ability to serve as a prognostic biomarker for patient outcomes.
Approach involved an analysis of lactylation-associated gene signatures in glioblastoma to determine predictive value.
This finding may enable personalized treatment strategies for glioblastoma based on genomic profiles.

Implication

Analysis reveals a prognostic biomarker in glioblastoma, suggesting novel pathways for personalized treatment strategies.

Abstract

The lactylation-related gene signature established in this study demonstrates robust predictive efficacy in glioblastoma, serving not only as a prognostic biomarker but also offering new directions for personalized treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/692b943e1d383f2b2a378970 https://doi.org/10.1007/s12672-025-04017-6

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals a prognostic biomarker in glioblastoma, suggesting novel pathways for personalized treatment strategies.

Prognostic and therapeutic response prediction in glioblastoma multiforme using a lactylation-associated gene signature

Key Points

Implication

Abstract

Discussion

Cite This Study

Prognostic and therapeutic response prediction in glioblastoma multiforme using a lactylation-associated gene signature

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading